TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?

被引：41
|
作者：
Gram, Dorte X. [1 ]
Holst, Jens J. [2 ]
Szallasi, Arpad [3 ]
机构：
[1] Pila Pharma, Malmo, Sweden
[2] Univ Copenhagen, Panum Inst, Copenhagen, Denmark
[3] Baptist Med Ctr, Jacksonville, FL USA
来源：
TRENDS IN MOLECULAR MEDICINE | 2017年 / 23卷 / 11期
关键词：
GENE-RELATED PEPTIDE; SENSORY NERVE DESENSITIZATION; SUBSTANCE-P; INSULIN-SECRETION; GLUCOSE-TOLERANCE; PERIPHERAL NEUROPATHY; INFLAMMATORY MARKERS; VANILLOID RECEPTOR-1; CAPSAICIN RECEPTORS; ISLET INFLAMMATION;
D O I：
10.1016/j.molmed.2017.09.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is a polygenic disease with a chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents with proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt disease progression and improve glucose metabolism. Thus, we propose that TRPV1 antagonists merit further study as novel therapeutic approaches to potentially treat T2D and its comorbidities.
引用
收藏
页码：1002 / 1013
页数：12
相关论文
共 50 条
  • [21] TRPV1: A promising therapeutic target for skin aging and inflammatory skin diseases
    Xiao, Tengfei
    Sun, Mingzhong
    Zhao, Chuanxiang
    Kang, Jingjing
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [22] COL1A1 as a potential new biomarker and therapeutic target for type 2 diabetes
    Lin, Guopeng
    Wan, Xuzhi
    Liu, Dan
    Wen, Yuxi
    Yang, Chengfeng
    Zhao, Chao
    PHARMACOLOGICAL RESEARCH, 2021, 165
  • [23] Analgesic potential of TRPV1 antagonists
    Kym, Philip R.
    Kort, Michael E.
    Hutchins, Charles W.
    BIOCHEMICAL PHARMACOLOGY, 2009, 78 (03) : 211 - 216
  • [24] TRPV1: A Target for Rational Drug Design
    Carnevale, Vincenzo
    Rohacs, Tibor
    PHARMACEUTICALS, 2016, 9 (03)
  • [25] THE TRPV1 CHANNEL AS A TARGET FOR THE TREATMENT OF PAIN
    Salazar, H.
    Jara-Oseguera, A.
    Rosenbaum, T.
    REVISTA DE NEUROLOGIA, 2009, 48 (07) : 357 - 364
  • [26] TRPV1: A target for next generation analgesics
    Premkumar, Louis S.
    Sikand, Parul
    CURRENT NEUROPHARMACOLOGY, 2008, 6 (02) : 151 - 163
  • [27] Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target
    Mistretta, Francesco
    Buffi, Nicolo Maria
    Lughezzani, Giovanni
    Lista, Giuliana
    Larcher, Alessandro
    Fossati, Nicola
    Abrate, Alberto
    Dell'Oglio, Paolo
    Montorsi, Francesco
    Guazzoni, Giorgio
    Lazzeri, Massimo
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [28] Multisteric TRPV1 nocisensor: a target for analgesics
    Szolcsanyi, Janos
    Sandor, Zoltan
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (12) : 646 - 655
  • [29] The TRPV1 receptor: Target of toxicants and therapeutics
    Veronesi, B
    Oortgiesen, M
    TOXICOLOGICAL SCIENCES, 2006, 89 (01) : 1 - 3
  • [30] Is TRPV1 a useful target in respiratory diseases?
    Takemura, Masaya
    Quarcoo, David
    Niimi, Akio
    Dinh, Q. Thai
    Geppetti, Pierangelo
    Fischer, Axel
    Chung, K. Fan
    Groneberg, David A.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2008, 21 (06) : 833 - 839
12345